ورود
مقالات فارسیISIکنفرانسهاژورنالها

Biological alterations in renal and hepatic tissues by a novel gold (III) anti-cancerous compound

محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 21، شماره: 10
سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 144

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1295220

شناسه ملی سند علمی:

JR_IJBMS-21-10_012

تاریخ نمایه سازی: 27 مهر 1400

چکیده مقاله:

Objective(s): Newer organo-metallic, specifically gold (III) complexes with multiple ligands are currently being formulated with primary focus of having increased anti-cancerous properties and decreased cytotoxicity. In this study, histological toxicity profile of a newly formulated anti-cancerous gold (III) compound [trans-(±)-۱,۲-(DACH)۲Au]Cl۳ Bis(trans-۱,۲-Diaminocyclohexane) was investigated by evaluation of kidney and liver tissues of treated rats.Materials and Methods: This is a quasi-experimental study. In acute toxicity component of the study, (n = ۱۶) male rats weighing between ۲۰۰–۲۵۰ g were administered single, variable concentration of the gold (III) compound, [trans-(±)-۱,۲-(DACH)۲Au]Cl۳ Bis(trans-۱,۲-Diaminocyclohexane) to determine LD۵۰ (dose that is lethal to ۵۰% of rats). An IP injection of ۲.۳ mg/kg (equivalent to ۱/۱۰ of LD۵۰) was injected for ۱۴ consecutive days to (n=۱۰) male rats in the sub-acute component of the study. Autopsy preservation of liver and kidney tissue in buffered formalin, sample processing, histopathological evaluation, and comparison with unremarkable controls (n=۵) was conducted sequentially. Results: A dose of ۲.۳ mg/kg did not produce any tubular necrosis in kidney specimens. Mild interstitial inflammation with prominence of plasma cells was the main histological alteration. Plasmacytic pyelitis was also seen. Varying extents of cytoplasmic vacuolization and mild focal lobular and portal inflammation were predominant hepatic microscopic findings. Conclusion: [trans-(±)-۱,۲-(DACH)۲Au]Cl۳ Bis(trans-۱,۲-Diaminocyclohexane) produced no histological damage in renal and hepatic tissues of rats. This very limited sample animal-based study points to the relative safety of this new gold compound. However, there is a need to compare this compound with established drugs in a comparative non-animal based study.

کلیدواژه ها:

Anticancerous ، Kidney ، Liver ، Novel gold III compound ، Toxicity

نویسندگان

Ayesha Ahmed

Department of Pathology, College of Medicine and King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Abdulaziz M Mansour Alkhawajah

Department of Pharmacology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Dalal M Al-Tamimi

Department of Pathology, College of Medicine and King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Muhammad A Shwarby

Department of Pathology, College of Medicine and King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Anvarhusein A Isab

Department of Chemistry, King Fahd University of Petroleum & Minerals, Dhahran, Saudi Arabia

Ahmed Badar

Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Nardon C, Boscutti G, Fregona D. Beyond platinums: gold complexes ...
  • Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, ...
  • Olszewski U, Hamilton G.A better platinum-based anticancer drug yet to ...
  • Janković SM, Djeković A, Bugarčić Z, Janković SV, Lukić G, ...
  • Gabbiani C, Casini A, Messori L. Gold (III) compounds as ...
  • Kalayda GV, Wagner CH, Jaehde U. Relevance of copper transporter ...
  • Buckley RG, Elsome AM, Fricker SP, Henderson GR, Theobald BR, ...
  • Ahmed A, Al Tamimi DM, Isab AA, Alkhawajah AM, Shawarby ...
  • Al-Jaroudi SS, Monim-ul-Mehboob M, Altaf M, Fettouhi M, Wazeer MIM, ...
  • Miller LC, Tainter MI. Estimation of LD۵۰ or ED۵۰ values ...
  • Underwood JCE. Histochemistry, Theoretical and Applied. Vol. ۲: Analytical technology ...
  • Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, ...
  • Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. ...
  • Arsenijević M, Milovanovic M, Volarevic V, Djeković A, Kanjevac T, ...
  • Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. ...
  • Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J ...
  • Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents:clinical manifestations, pathobiology, ...
  • Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. ...
  • Aldinucci D, Lorenzon D, Stefani L, Giovagnini L, Colombatti A, ...
  • Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with ...
  • Ciarimboli G, Holle SK, Vollenbröcker B, Hagos Y, Reuter S, ...
  • Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular ...
  • Perazella MA. Crystal-induced acute renal failure. Am J Med ۱۹۹۹; ...
  • Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ...
  • Avci A, Cetin R, Erguder IB, Devrim E, Kilicoglu B, ...
  • Grigorian A, O’Brien CB. Hepatotoxicity Secondary to Chemotherapy. J Clin ...
  • Tsui W MS. Drug-associated changes in the liver. Curr Diagn ...
  • Lefkowitch JH. Histological assessment of cholestasis. Clin Liver Dis ۲۰۰۴; ...
  • Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in ...
  • Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, ...
  • Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, ...
  • Rothbarth J, Pigil MEJ, Vahrmeijer AL. Isolated hepatic perfusion with ...
  • Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy-efficacy, safety, and ...
  • Tran A, Housset C, Boboc B, Tourani JM, Carnot F, ...
  • Teo YL, Ho HK, Chan A. Risk of tyrosine kinase ...
  • Liu J, Liu Y, Habeebu SS, Klaassen CD. Metallothionein (MT)-null ...
  • Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. ...
  • Kart A, Cigremis Y, Karaman M, Ozen H. Caffeic acid ...
  • Li X, Elwell MR, Ryan AM, Ochoa R. Morphogenesis of ...
    • نمایش کامل مراجع